Welcome to our dedicated page for BIOXYTRAN news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on BIOXYTRAN stock.
Bioxytran, Inc., an early stage pharmaceutical company, focuses on the development, manufacture, and commercialization of various therapeutic drugs to address hypoxia in humans. The company's lead pharmaceutical drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for the treatment of patients with ischemia of the brain resulting from a stroke or blockage of the blood vessels to the brain. Its products also include BXT-252, an injectable anti-necrosis drug to treat a wound that does not heal because of a limited amount of oxygen reaching the wound. The company was founded in 2017 and is headquartered in Newton, Massachusetts.
BIOXYTRAN, INC. (BIXT) announced successful animal testing results for its Acellular Oxygen Carrier BXT-25, designed to treat COVID-19 and other viral diseases. The treatment showed non-toxicity and full recovery in Swiss Albino mice, even after a significant blood loss. BXT-25 is significantly smaller than a blood cell, allowing it to reach hypoxic areas of the body, potentially revolutionizing treatment for conditions like strokes and neurodegenerative diseases. The company plans to conduct further toxicity studies and aims to submit an Investigational New Drug Application to the FDA for clinical trials on stroke patients. Initial non-clinical studies indicated no toxicity and effective oxygen delivery, bolstering the drug's therapeutic potential.
BIOXYTRAN, INC. (OTCQB: BIXT) is set to present new findings on its Long COVID research at the Emerging Growth Conference on April 5, 2023, from 10:50am to 11:20am EST. CCO Michael Sheikh will discuss a recent peer-reviewed journal article and engage with attendees. Investors are encouraged to preregister for the event to receive updates and have the opportunity to submit questions. Bioxytran is developing innovative antiviral treatments, focusing on unmet medical needs in virology. The conference serves as a platform for public companies to showcase advancements, attracting a broad audience of investors.
Bioxytran, Inc. (BIXT) announced promising results from a Phase 2 clinical trial for its Galectin antagonist, demonstrating a 100% viral load elimination in 34 patients with mild-to-moderate COVID-19 by day 7, compared to just 6% in the placebo group (p=.001). Most symptoms resolved within the same period. The trial showed an 82% responder rate by day 3 (p=.001) with no serious adverse events. These results support further studies, possibly a Phase 3 trial, highlighting the drug's potential in both treatment and prophylaxis against viral infections. Bioxytran aims to explore applications beyond COVID-19, tapping into Glycovirology.
Bioxytran, Inc. (OTCQB: BIXT) has reported promising in vitro results for its leading drug candidate ProLectin-M (PL-M), demonstrating a significant reduction in viral load for influenza (H1N1) and Respiratory Syncytial Virus (RSV). Conducted at the Foundation for Neglected Disease Research in India, these tests mirror previous SARS-CoV-2 results that led to successful trials. The company plans to file an IND to advance to phase 2 human clinical trials. With this data, Bioxytran aims to expand treatment options for viral diseases amid the rise of concurrent infections known as the 'tripledemic.'
BIOXYTRAN, INC. (OTCQB: BIXT) has announced that a peer-reviewed article published in Nature Reviews Drug Discovery supports its drug development for fibrosis and antiviral treatments. The article, titled “Targeting galectin-driven regulatory circuits in cancer and fibrosis”, highlights the significance of galectins in diseases like Idiopathic Pulmonary Fibrosis (IPF) and Long COVID. ProLectin-M, an oral drug, showed a 100% responder rate in clinical trials for COVID-19, while ProLectin-I, an intravenous drug, aims to tackle Long COVID and IPF. The ongoing studies and supportive literature enhance the prospects for regulatory approval.
Bioxytran, Inc. (OTCQB: BIXT) announced that CCO Michael Sheikh will participate in a ClearThink IR Virtual Live event on February 15, 2023, at 12 PM ET. The event, hosted via the Paltalk platform, aims to engage potential investors with Q&A discussions about the company’s innovative therapies targeting viral diseases and other medical needs. Bioxytran is focused on developing Prolectin-M, a new class of antiviral drug, along with treatments for pulmonary fibrosis and stroke. Registration for the event is available on their website.
FAQ
What is the current stock price of BIOXYTRAN (BIXT)?
What is the market cap of BIOXYTRAN (BIXT)?
What is the focus of Bioxytran, Inc.?
What is the lead pharmaceutical drug candidate of the company?
What is BXT-252?
When was Bioxytran, Inc. founded?
Where is Bioxytran, Inc. headquartered?
What are the contact details for Investor Relations at Bioxytran, Inc.?
What recent achievement has Bioxytran, Inc. made in lesion clearance and regression of Herpes Zoster Neuralgia?
What does the company's patent cover?
What products are included in Bioxytran, Inc.'s portfolio?
What kind of therapeutic drugs does Bioxytran, Inc. manufacture?
